Dr. John Cush RheumNow
5 years 6 months ago
The Reflecting Rheum: Top Publications from 2020 Covering SpA and Still’s Disease
Sponsored by Novartis Medical Affairs
Listen to a panel of experts share their views on top spondyloarthritis and Still’s disease publications from 2020.
View Now: https://t.co/rxTAwQNalx https://t.co/LMHLqpXKgs
Dr Jack Cush reviews the news, Journal reports, CDC guidelines and viewer questions from the last week on RheumNow.com
Dr. John Cush RheumNow
5 years 6 months ago
Intraarticular Steroids in OA - They Dont work & Not Safe
https://t.co/fB9SDFMVgf https://t.co/kk2VauefAe
JAMA reports a safety survey of hospital employees showing that the risk of anaphylaxis from mRNA vaccines is 2.47 per 10,000 individuals.
Prior studies suggested the risk of anaphylaxis to the mRNA COVID-19 vaccines may be as low as 2.5 - 11.1 cases per million doses and that such reactions are more likely in those with a history of allergy.
Dr. John Cush RheumNow
5 years 6 months ago
Metanalysis of 45 studies, ∼175 000 individuals shows a significant association between pain and socioeconomic status (SES).Chronic pain was higher with low SES (OR 1.32) and medium SES level (OR 1.16) https://t.co/0MM0V1WUhi
Dr. John Cush RheumNow
5 years 6 months ago
Population claims based study of RA patients shows improvement in the 10-year risk of acute myocardial infarction over time (same as the general population). Nevertheless, RA pts have a 21 % higher risk of AMI than the matched general population https://t.co/zfsJftR9ZA
Dr. John Cush RheumNow
5 years 6 months ago
Free read on the 20 year history, immunology and targeting of interleukin-17 (IL-17) Great article by Professor Pierre Miossec https://t.co/69acTuPWZZ
Dr. John Cush RheumNow
5 years 6 months ago
We are just about one week out. Have you registered to attend? We have a robust schedule planned with digital access to all content and downloads.
https://t.co/Woxi4Ri0O5 https://t.co/ADll6r8dFu
There is a growing body of evidence regarding COVID-19 outcomes (including death) in rheumatic disease patients; analysis of a German registry shows that poor control, rituximab, sulfasalazine and other immunosuppressives could be risk factors for COVID-related death.
Dr. John Cush RheumNow
5 years 6 months ago
QD Clinic - Notalgia?
Get a Clue - to the Dx of FM
https://t.co/LRC7e8PPla https://t.co/K4pkWq39OC
Dr. John Cush RheumNow
5 years 6 months ago
RheumNow Live is a powerful, interactive meeting delivered by researchers, educators, & clinicians.
Sign up to attend virtually or in-person today.
https://t.co/LJ3qClHTKh https://t.co/K3YgfFZhpa
On Feb. 27, the Food and Drug Administration announced it has issued an emergency use authorization for Johnson & Johnson’s one-dose Covid vaccine, making it the third COVID-19 vaccine to be commercially available. We've compiled a comparison table and some key information relevant to your delivering patient guidance henceforth.
Dr. John Cush RheumNow
5 years 6 months ago
QD Clinic - Ms. RA
Can Multiple Sclerosis and RA Coexist? What Drugs can be used?
https://t.co/PYFQI7vn3M
